05/05/2025 – AB Science announced that new analyses from its phase 3 trial in ALS and preclinical animal model data have been accepted for presentation at the ENCALS annual meeting (June 3-6, 2025, Turin, Italy)
01/05/2025 – AB Science today announced that it has postponed the publication of its 2024 annual financial report, initially scheduled for 30 April 2025, to give the auditors time to complete their audit work
23/04/2025 – AB Science announces today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) granted orphan drug status to AB8939 for the treatment of acute myeloid leukemia (AML)
14/04/2025 – AB Science today announced that the United States Patent Office has issued a Notice of Allowance for a patent relating to methods of treating sickle cell disease with its lead compound masitinib, based on preclinical data
04/03/2025 – AB Science today announces that The Life Sciences Magazine, a leading publication in the fields of healthcare and medical advancements, has featured an exclusive cover story on Professor Patrick Vermersch, principal investigator of phase 3 confirmatory study with masitinib in progressive forms of multiple sclerosis
29/01/2025 – AB Science provides a summary of the webcast held on January 28, 2025
28/01/2025 – Presentation of the AB Science webcast held on January 28, 2025
24/01/2025 – AB Science will host a live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CET
22/01/2025 – AB Science announced that its management team will participate in the upcoming edition of the Biomed Forum, a conference for institutional investors, that will take place on February 4, 2025, in Paris